{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:42:45Z","timestamp":1791049365443,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,5,1]]},"abstract":"<jats:p>Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of hypereosinophilic syndrome (HES) and a rare eosinophilia-associated chronic myeloid disorder (eos-CMD) characterized by the t(5;12)(q33;p13) cytogenetic abnormality. In the current study, we sought to confirm the preliminary observations in HES as well as evaluate the therapeutic value of imatinib in eos-CMD that is not associated with t(5;12)(q33;p13). Five patients with HES (all men, median age\u2009=\u200946 years) and 2 with eos-CMD (both men, aged 45 and 58 years) were treated with imatinib at a starting dose of 100 to 400 mg\/day. Cytogenetic studies showed no evidence of either the bcr-abl translocation or t(5;12)(q33;p13) in any patient. Screening of exons encoding the intracellular catalytic domains and extracellular ligand binding domains of PDGFR\u03b2 (exons 2-23) and c-kit (exons 1-21) in 6 patients demonstrated mostly previously known polymorphisms. At a median follow-up of 17 weeks (range, 10-33 weeks), 2 patients with HES and 1 with eos-CMD have achieved complete clinical remission and 1 additional patient with HES has achieved a partial remission. In contrast to previous observations, all 4 responding patients had elevated serum interleukin-5 levels. Although the drug was well tolerated in most patients, a previously unrecognized treatment toxicity of acute left ventricular dysfunction occurred in a responding patient with HES within the first week of treatment. Myocardial biopsy revealed eosinophilic infiltration and degranulation, and the cardiogenic shock was reversed with the prompt institution of corticosteroid therapy.<\/jats:p>","DOI":"10.1182\/blood-2002-10-3103","type":"journal-article","created":{"date-parts":[[2003,4,21]],"date-time":"2003-04-21T13:30:06Z","timestamp":1050931806000},"page":"3391-3397","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":172,"title":["Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders"],"prefix":"10.1182","volume":"101","author":[{"given":"Animesh","family":"Pardanani","sequence":"first","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra","family":"Reeder","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Porrata","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Yang","family":"Li","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry D.","family":"Tazelaar","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Joanna","family":"Baxter","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Internal Medicine, Hematopathology, and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111820522318300_B1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood.V84.1.349.349","article-title":"Clonal nature of hypereosinophilic syndrome.","volume":"84","author":"Luppi","year":"1994","journal-title":"Blood."},{"key":"2019111820522318300_B2","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood.V93.5.1651.405k20_1651_1657","article-title":"Clonality of isolated eosinophils in the hypereosinophilic syndrome.","volume":"93","author":"Chang","year":"1999","journal-title":"Blood."},{"key":"2019111820522318300_B3","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.4049\/jimmunol.139.11.3753","article-title":"T lymphocyte control of human eosinophilic granulopoiesis: clonal analysis in an idiopathic hypereosinophilic syndrome.","volume":"139","author":"Raghavachar","year":"1987","journal-title":"J Immunol."},{"key":"2019111820522318300_B4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJM199402243300804","article-title":"Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome.","volume":"330","author":"Cogan","year":"1994","journal-title":"N Engl J Med."},{"key":"2019111820522318300_B5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2141.1996.d01-1482.x","article-title":"Eosinophilia associated with proliferation of CD(3+)4-(8-) alpha beta+ T cells with chromosome 16 anomalies.","volume":"92","author":"Kitano","year":"1996","journal-title":"Br J Haematol."},{"key":"2019111820522318300_B6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0091-6749(98)70279-9","article-title":"Role of gamma\/delta T cells in a patient with CD4+CD3- lymphocytosis, hypereosinophilia, and high levels of IgE.","volume":"102","author":"Bank","year":"1998","journal-title":"J Allergy Clin Immunol."},{"key":"2019111820522318300_B7","first-page":"9","article-title":"Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.","volume":"3","author":"Schaller","year":"2001","journal-title":"Med Gen Med."},{"key":"2019111820522318300_B8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","article-title":"Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.","volume":"26","author":"Ault","year":"2002","journal-title":"Leuk Res."},{"key":"2019111820522318300_B9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate.","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet."},{"key":"2019111820522318300_B10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med."},{"key":"2019111820522318300_B11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1987.tb02291.x","article-title":"Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association.","volume":"67","author":"Keene","year":"1987","journal-title":"Br J Haematol."},{"key":"2019111820522318300_B12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.","volume":"77","author":"Golub","year":"1994","journal-title":"Cell."},{"key":"2019111820522318300_B13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ng0198-84","article-title":"FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia\/lymphoma syndrome.","volume":"18","author":"Xiao","year":"1998","journal-title":"Nat Genet."},{"key":"2019111820522318300_B14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood.V95.5.1788.005k15_1788_1796","article-title":"FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).","volume":"95","author":"Guasch","year":"2000","journal-title":"Blood."},{"key":"2019111820522318300_B15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V93.4.1381","article-title":"The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1.","volume":"93","author":"Popovici","year":"1999","journal-title":"Blood."},{"key":"2019111820522318300_B16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","article-title":"The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1.","volume":"107","author":"Macdonald","year":"2002","journal-title":"Acta Haematol."},{"key":"2019111820522318300_B17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<137::AID-AJH9>3.0.CO;2-T","article-title":"Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation.","volume":"58","author":"Yamada","year":"1998","journal-title":"Am J Hematol."},{"key":"2019111820522318300_B18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0165-4608(98)00099-5","article-title":"Chronic eosinophilic leukemia and hypereosinophilic syndromes: proposal for classification, literature review, and report of a case with a unique chromosomal abnormality.","volume":"107","author":"Oliver","year":"1998","journal-title":"Cancer Genet Cytogenet."},{"key":"2019111820522318300_B19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1365-2141.1997.d01-1991.x","article-title":"Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease.","volume":"96","author":"Weide","year":"1997","journal-title":"Br J Haematol."},{"key":"2019111820522318300_B20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00062752-200001000-00005","article-title":"Hypereosinophilia.","volume":"7","author":"Bain","year":"2000","journal-title":"Curr Opin Hematol."},{"key":"2019111820522318300_B21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0165-4608(98)00055-7","article-title":"Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ hybridization.","volume":"107","author":"Forrest","year":"1998","journal-title":"Cancer Genet Cytogenet."},{"key":"2019111820522318300_B22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med."},{"key":"2019111820522318300_B23","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood."},{"key":"2019111820522318300_B24","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood."},{"key":"2019111820522318300_B25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med."},{"key":"2019111820522318300_B26","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med."},{"key":"2019111820522318300_B27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0165-4608(95)00021-6","article-title":"Acute myeloblastic leukemia (M2) with translocation (7;11) followed by marked eosinophilia and additional abnormalities of chromosome 5.","volume":"83","author":"Abe","year":"1995","journal-title":"Cancer Genet Cytogenet."},{"key":"2019111820522318300_B28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.186.2.313","article-title":"Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)-mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1).","volume":"186","author":"Yuan","year":"1997","journal-title":"J Exp Med."},{"key":"2019111820522318300_B29","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.V97.4.1086","article-title":"Human peripheral blood eosinophils express stem cell factor.","volume":"97","author":"Hartman","year":"2001","journal-title":"Blood."},{"key":"2019111820522318300_B30","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/blood.V100.13.4291","article-title":"Stem cell factor induces eosinophil activation and degranulation: mediator release and gene array analysis.","volume":"100","author":"Oliveira","year":"2002","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/9\/3391\/1256858\/h80903003391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/9\/3391\/1256858\/h80903003391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T01:27:41Z","timestamp":1682472461000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/9\/3391\/105823\/Imatinib-therapy-for-hypereosinophilic-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,1]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-10-3103","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5,1]]}}}